These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 29530335)
1. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
3. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Shinozaki K; Yamada T; Nasu J; Matsumoto T; Yuasa Y; Shiraishi T; Nagano H; Moriyama I; Fujiwara T; Miguchi M; Yoshida R; Nozaka K; Tanioka H; Nagasaka T; Kurisu Y; Kobayashi M; Tsuchihashi K; Inukai M; Kikuchi T; Nishina T Int J Clin Oncol; 2021 Feb; 26(2):399-408. PubMed ID: 33097971 [TBL] [Abstract][Full Text] [Related]
5. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. Bando H; Kotani D; Satake H; Hamaguchi T; Shiozawa M; Kotaka M; Masuishi T; Yasui H; Kagawa Y; Komatsu Y; Oki E; Yamamoto Y; Kawakami H; Misumi T; Taniguchi H; Yamazaki K; Muro K; Yoshino T; Kato T; Tsuji A Med; 2024 Sep; 5(9):1164-1177.e3. PubMed ID: 38901425 [TBL] [Abstract][Full Text] [Related]
6. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
7. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200 [TBL] [Abstract][Full Text] [Related]
8. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
9. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
10. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608 [TBL] [Abstract][Full Text] [Related]
11. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C Ann Oncol; 2019 Dec; 30(12):1969-1977. PubMed ID: 31573612 [TBL] [Abstract][Full Text] [Related]
12. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863 [TBL] [Abstract][Full Text] [Related]
14. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730 [TBL] [Abstract][Full Text] [Related]
15. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572 [TBL] [Abstract][Full Text] [Related]